- Home
- ARCT vs TARA Comparison
ARCT vs TARA Comparison
Compare ARCT & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARCT | TARA |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.1M | 236.1M |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ARCT | TARA |
|---|---|---|
| Price | $5.52 | $4.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | $24.11 | ★ $24.40 |
| AVG Volume (30 Days) | 564.0K | ★ 690.8K |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 20.00 | ★ 38.25 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $82,031,000.00 | $2,948,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.77 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.74 | $2.97 |
| 52 Week High | $24.14 | $7.82 |
Technical Indicators
Market Signals| Indicator | ARCT | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 26.97 | 45.92 |
| Support Level | N/A | $3.69 |
| Resistance Level | $7.98 | $4.23 |
| Average True Range (ATR) | 0.36 | 0.19 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 0.23 | 20.91 |
Price Performance
Historical ComparisonAbout ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.